Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
44
SBMFF Quote, Financials, Valuation and Earnings
Last price:
$0.41
Seasonality move
:
11.41%
Day range:
$0.41 - $0.41
52-week range:
$0.31 - $0.47
Dividend yield:
2.49%
P/E ratio:
24.26x
P/S ratio:
1.97x
P/B ratio:
1.66x
Volume:
--
Avg. volume:
696
1-year change:
-1.06%
Market cap:
$7.5B
Revenue:
$3.7B
EPS (TTM):
$0.02
Analysts' Opinion
-
Consensus RatingSino Biopharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Sino Biopharmaceutical has an estimated downside of -- from its current price of $0.41.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.41.
Fair Value
-
According to the consensus of 0 analysts, Sino Biopharmaceutical has -- downside to fair value with a price target of -- per share.
SBMFF vs. S&P 500
-
Over the past 5 trading days, Sino Biopharmaceutical has underperformed the S&P 500 by -4.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sino Biopharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sino Biopharmaceutical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported revenues of --.
Earnings Growth
-
Sino Biopharmaceutical has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported earnings per share of --.
Enterprise value:
8.3B
EV / Invested capital:
--
Price / LTM sales:
1.97x
EV / EBIT:
9.39x
EV / Revenue:
2.14x
PEG ratio (5yr expected):
3.02x
EV / Free cash flow:
11.62x
Price / Operating cash flow:
10.70x
Enterprise value / EBITDA:
9.39x
Gross Profit (TTM):
$3.1B
Return On Assets:
6.27%
Net Income Margin (TTM):
14.72%
Return On Equity:
10.53%
Return On Invested Capital:
8.21%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $3.5B | $3.5B | $2.4B | $906.2M | $1.1B | |
| Gross Profit | -- | -- | -- | $691.1M | $893.5M | |
| Operating Income | -- | -- | -- | $203.7M | $276.9M | |
| EBITDA | -- | -- | -- | $197.6M | $1.3B | |
| Diluted EPS | -- | -- | -- | $0.00 | $0.05 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.9B | $3.7B | $3.8B | $3.7B | $3.5B | |
| Total Assets | $9.6B | $8.7B | $9.7B | $9B | $9.2B | |
| Current Liabilities | $1.5B | $1.8B | $2.4B | $3.7B | $3B | |
| Total Liabilities | $3.8B | $3.9B | $3.9B | $4B | $3.4B | |
| Total Equity | $5.9B | $4.8B | $5.8B | $5B | $5.8B | |
| Total Debt | -- | -- | $1.7B | $1.5B | $1.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | $405.3M | $219.4M | $361.5M | |
| Cash From Investing | -- | -- | -- | -$216.3M | -$627.7M | |
| Cash From Financing | -- | -- | -- | $720.7M | -$117.9M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SBMFF
Sector
Market Cap
$7.5B
$45.6M
Price % of 52-Week High
86.96%
45.55%
Dividend Yield
2.49%
0%
Shareholder Yield
7.23%
-0.74%
1-Year Price Total Return
-1.06%
-31.35%
Beta (5-Year)
0.538
0.772
Dividend yield:
2.49%
Annualized payout:
$0.01
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.42
200-day SMA
Buy
Level
$0.38
Bollinger Bands (100)
Sell
Level
0.38 - 0.46
Chaikin Money Flow
Sell
Level
-2.2M
20-day SMA
Sell
Level
$0.43
Relative Strength Index (RSI14)
Sell
Level
34.68
ADX Line
Sell
Level
19.93
Williams %R
Buy
Level
-99.5338
50-day SMA
Sell
Level
$0.44
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
4.1M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5383)
Buy
CA Score
(Annual)
Level (-0.0244)
Buy
Beneish M-Score
(Annual)
Level (-2.546)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.2543)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP’s current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
Stock Forecast FAQ
In the current month, SBMFF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBMFF average analyst price target in the past 3 months is --.
-
Where Will Sino Biopharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sino Biopharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Sino Biopharmaceutical?
Analysts are divided on their view about Sino Biopharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sino Biopharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Sino Biopharmaceutical's Price Target?
The price target for Sino Biopharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBMFF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sino Biopharmaceutical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SBMFF?
You can purchase shares of Sino Biopharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sino Biopharmaceutical shares.
-
What Is The Sino Biopharmaceutical Share Price Today?
Sino Biopharmaceutical was last trading at $0.41 per share. This represents the most recent stock quote for Sino Biopharmaceutical. Yesterday, Sino Biopharmaceutical closed at $0.41 per share.
-
How To Buy Sino Biopharmaceutical Stock Online?
In order to purchase Sino Biopharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
